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Abstract
Background: The mammalian target of rapamycin complex 1 (mTORC1) is a central node in a network of signaling
pathways controlling cell growth and survival. This multiprotein complex integrates external signals and affects
different nutrient pathways in various organs. However, it is not clear how alterations of mTORC1 signaling in
skeletal muscle affect whole-body metabolism.
Results: We characterized the metabolic phenotype of young and old raptor muscle knock-out (RAmKO) and TSC1
muscle knock-out (TSCmKO) mice, where mTORC1 activity in skeletal muscle is inhibited or constitutively activated,
respectively. Ten-week-old RAmKO mice are lean and insulin resistant with increased energy expenditure, and they
are resistant to a high-fat diet (HFD). This correlates with an increased expression of histone deacetylases (HDACs)
and a downregulation of genes involved in glucose and fatty acid metabolism. Ten-week-old TSCmKO mice are
also lean, glucose intolerant with a decreased activation of protein kinase B (Akt/PKB) targets that regulate glucose
transporters in the muscle. The mice are resistant to a HFD and show reduced accumulation of glycogen and lipids
in the liver. Both mouse models suffer from a myopathy with age, with reduced fat and lean mass, and both
RAmKO and TSCmKO mice develop insulin resistance and increased intramyocellular lipid content.
Conclusions: Our study shows that alterations of mTORC1 signaling in the skeletal muscle differentially affect
whole-body metabolism. While both inhibition and constitutive activation of mTORC1 induce leanness and
resistance to obesity, changes in the metabolism of muscle and peripheral organs are distinct. These results indicate
that a balanced mTORC1 signaling in the muscle is required for proper metabolic homeostasis.
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Background
The highly conserved serine/threonine protein kinase
mammalian target of rapamycin (mTOR) is known to
control numerous cellular processes related to cell
growth [45]. mTOR assembles into two functionally dis-
tinct multiprotein complexes, the rapamycin-sensitive
mTOR complex 1 (mTORC1) and mTORC2, which is
only sensitive to prolonged rapamycin treatment [33].
mTORC1 is a central sensor of growth factors and nutri-
ents in various cell types and has been described to play
an important role in different pathologies like cancer,
metabolic diseases, and aging [21]. Because of its central
role in metabolism, the mTOR pathway is extensively
studied for its function in type 2 diabetes [29]. mTORC1
is also highly active in the liver and skeletal muscle of
obese and high-fat-fed rodents [17, 42]. Inhibition of
mTOR signaling by rapamycin prolongs lifespan in sev-
eral species including mice [15], a treatment that has
been proposed to mimic calorie restriction [36]. Para-
doxically, prolonged treatment with rapamycin causes
glucose intolerance and insulin resistance [10, 13, 16],
which has been interpreted to be the result of the inacti-
vation of mTORC2 [20]. In the skeletal muscle,
mTORC1 regulates muscle mass by affecting both pro-
tein synthesis and degradation [21].
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As it is difficult to distinguish the contribution of dif-
ferent tissues on the systemic effects of rapamycin treat-
ment, several laboratories have generated various mouse
models with tissue-specific deletions of essential compo-
nents of the mTORC1 pathway. White adipose tissue
(WAT)-specific deletion of rptor (gene coding for rap-
tor), which is essential for the activity of mTORC1, leads
to improved insulin sensitivity and reduced adipocyte
number and size [27]. Inactivation of mTORC1 in the
liver leads to resistance to hepatic steatosis and hyper-
cholesteremia induced by a Western diet [26]. While
those tissues are the primary sites controlling metabol-
ism, the skeletal muscle has also been shown to contrib-
ute to whole-body metabolism. For example, the skeletal
muscle is the major site of glucose uptake in response to
food intake and insulin and thus can contribute to type
2 diabetes [11]. Accordingly, patients with muscular
dystrophies often develop metabolic complications like
glucose intolerance and insulin resistance [30, 34]. Simi-
larly, sustained activation of mTORC1 leads to metabolic
changes at the whole-body level [14].
In this study, we compared as to how activation or in-
activation of mTORC1 in the skeletal muscle affect sys-
temic energy homeostasis. We show that both fatty acid
and glucose metabolism are dependent on proper
mTORC1 signaling. In mice with muscle-specific deple-
tion of raptor (i.e., inactive mTORC1), the metabolic
changes correlate with the upregulation of class II his-
tone deacetylases (HDACs). On the contrary, muscle-
specific depletion of tuberous sclerosis complex 1
(TSC1) (i.e., constant activation of mTORC1) leads to an
upregulation of transcripts involved in glucose and fatty
acid metabolism in various metabolic organs [14] but
causes glucose intolerance and late-onset damage in
both the liver and the kidneys. These data thus provide
evidence that mTORC1 signaling in the skeletal muscle
is a major regulator of whole-body metabolism and they
suggest that muscle mTORC1 could be a valuable target
for the treatment of metabolic complications associated
with muscle diseases including muscular dystrophies.
Material and methods
Animal experiments
Generation of TSC1 muscle knock-out (TSCmKO) and
raptor muscle knock-out (RAmKO) mice and their
genotyping were described before [5, 7, 18]. Control
mice were littermates floxed for Rptor (gene encoding
raptor) or Tsc1 but not expressing Cre recombinase.
TSCmKO and RAmKO mice were always compared to a
control group of littermates. Initial statistical analysis
was always done separately using the respective controls.
At the young age, control mice for RAmKO and
TSCmKO mice were pooled as those mice had the same
age and because statistics was not altered when
experimental groups were compared to non-pooled con-
trols. All data shown represent new cohorts of mice al-
though some of the metabolic phenotype of TSCmKO
mice have been published before [14]. The fact that
those data are confirmatory is mentioned throughout
the text. Mice were maintained in a conventional facility
with a fixed light cycle (23 °C—12-h dark-light cycle)
and were fed standard chow (KLIBA NAFAG, 1304811)
or a high-fat diet (HFD) containing 60 % fat (KLIBA
NAFAG, 2127.PH.A05) ad libitum. HFD was started at 8
or 10 weeks of age, respectively, for RAmKO and
TSCmKO mice and continued for 12 weeks. Body com-
position was determined by magnetic resonance with the
EchoMRI-100H body composition analyzer (EchoMRI™)
in immobilized conscious mice. In some experiments,
mice were intraperitoneally injected with insulin at
2 p.m. (0.75 U/kg, Humalog, Eli Lilly) after a 5-h fast
and euthanized 45 min after for tissue collection.
Euthanasia in the rest of the mice was performed at
10 a.m. after food removal at 6 a.m. of the same morn-
ing. Both male and female mice were used for this study
after confirming that the phenotype observed was not
dependent on gender. Data from male mice are shown
in the main figures, whereas results from female mice,
when available, are shown in the Additional files. All
procedures were performed in accordance with the Swiss
regulations for animal experimentation and approved by
the veterinary commission of the Canton Basel-Stadt.
Metabolic measurements
Glucose, lactate, and insulin plasma levels were analyzed in
tail vein blood after a 4-h fast (6 a.m. to 10 a.m.) with One
Touch Ultra Easy glucose meter (LifeScan, Inc.), Lactate
Pro test strips (Arkray Factory, Inc.), and Ultra-Sensitive
Mouse Insulin ELISA kit (Crystal Chem, Inc.), respectively.
ATP content and glycogen amount in the muscle and liver
were determined by using a luminescence assay (CellTiter-
Glo Luminescent Cell Viability Assay, Promega) and a
Glycogen assay kit (Sigma-Aldrich), respectively. A full
analysis of plasma parameters was performed with a cobas
C 111 machine (Roche) after a 4-h fast (6 a.m. to 10 a.m.).
Indirect calorimetry by Comprehensive Lab Animal
Monitoring System, Columbus Instruments (CLAMS)
Mice were acclimatized for 2 days (individual housing)
followed by data acquisition over 3 to 4 days. Activity
(i.e., ambulatory movement determined by laser counts
in X and Y coordinates), feeding, and drinking behaviors
were measured daily over a period of 4 days. Oxygen use
and carbon dioxide production was measured, and en-
ergy expenditure was calculated with the Weir equation.
Respiratory exchange ratio (RER) was calculated as car-
bon dioxide volume (VCO2)/oxygen volume (VO2). Data
were normalized to body weight.
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Intra-peritoneal (IP) insulin tolerance test (ITT) and
glucose tolerance test (GTT)
After an overnight starvation for GTT and a 5-h fast for
ITT (from 9 a.m. to 2 p.m.), mice were intraperitoneally
injected with 1.5 g/kg glucose (Merck) or 0.75 U/kg insulin
(Humalog, Eli Lilly), respectively. Basal blood glucose was
measured before the injection from tail vein blood and at
the indicated time points after the intraperitoneal injection.
Histology
The liver and tibialis anterior (TA) muscle, frozen in
liquid nitrogen-cooled isopentane, were cut into 10-
μm-thick cross sections. Sections were stained with
hematoxylin (Merck)-eosin (Sigma-Aldrich) and Oil
Red-O (Sigma-Aldrich) and mounted with glycerol
gelatin (Sigma-Aldrich).
Quantitative real-time PCR
Total RNA from RAmKO and control mice was isolated
(SV Total RNA isolation System, Promega), and equal
amounts of RNA were reverse transcribed using a mix-
ture of oligodT and random hexamer primers (iScript
cDNA Synthesis Kit, Bio-Rad). Quantitative real-time
PCR was performed using SYBR Green (Power SYBR
Green Master Mix, Applied Biosystems) and StepOne™
Software 2.1. (Applied Biosystems). Expression levels for
each gene of interest were normalized to the mean cycle
number using real-time PCR for the housekeeping gene-
encoding β-actin, whose expression was not altered
between RAmKO and control mice (Additional file 1:
Figure S1A). All experiments were performed in tripli-
cates. Primers used are listed in Additional file 2: Table S1.
Western blotting
Proteins were extracted from the TA muscle, liver, WAT,
and BAT as described previously [5]. Total protein levels
were determined using a reducing agent-compatible
BCA Protein Assay (Pierce). Signal was captured on a
Fusion Fx machine (Vilber Lourmat); gray values were
corrected for background and analyzed with the FU-
SION Capt FX software. Quantification of each protein
was normalized to the loading control (α-actinin or β-
actin). To determine the extent of protein phosphorylation,
relative intensity of the band using a phospho-specific anti-
body was divided by the amount of protein as determined
by a pan-specific antibody. Samples from the four groups
of mice were all run together on the same gel, and
quantification was done relative to the values of the
control group for each genotype. Antibodies are listed
in Additional file 1: Figure S1B.
Statistical analyses
Compiled data are expressed as mean ± SEM and n
(total number of knock-out mice). Measurements were
performed at least in three independent sets of experi-
ments. Statistical comparison of two conditions was per-
formed using the Student’s t test; comparison of three or
more groups was performed using the one-way or two-
way ANOVA test with Tukey’s correction for multiple
comparisons, and data where time was a variable were
analyzed by linear regression (GraphPad Prism Soft-
ware). A 0.05 level of confidence was accepted for statis-
tical significance.
Results
Modification of skeletal muscle mTORC1 signaling affects
whole-body metabolism
We have previously reported that inhibition of mTORC1
activity in the skeletal muscle by raptor depletion
(RAmKO mice) results in a lethal myopathy [5]. Inter-
estingly, sustained activation of mTORC1 by depletion
of TSC1 (TSCmKO mice) also results in a late-onset
myopathy [7]. In addition, RAmKO mice show alter-
ations in glucose metabolism in the muscle [5], whereas
TSCmKO show strong changes in their fatty acid metab-
olism at the whole-body level [14]. As the skeletal
muscle phenotypes of RAmKO and TSCmKO converge
at older age, we decided to also perform a detailed
characterization and comparison of RAmKO and
TSCmKO mice at the whole-body level.
First, we analyzed the body composition by EchoMRI
using 10-week-old mice, an age at which neither of the
mice show myopathic signs [4, 5, 7, 14]. Both male and fe-
male TSCmKO mice were significantly lighter when com-
pared to age-matched control mice (Fig. 1a; Additional file
1: Figure S2A). In RAmKO mice, male mice were also
lighter than their control littermates (Fig. 1a) while
this difference did not reach significance in females
(Additional file 1: Figure S2A). This difference in the
young RAmKO mice was due to a lower lean mass with-
out affecting the amount of fat (Fig. 1b, c; Additional file
1: Figure S2B and S2C). In young TSCmKO mice, lean
mass was moderately changed whereas the amount of fat
was strongly reduced (Fig. 1b, c; Additional file 1: Figure
S2B and S2C). RAmKO mice showed no changes in insu-
lin (Fig. 1d) and plasma glucose levels (Fig. 1e; Additional
file 1: Figure S2D), whereas those plasma parameters were
lower in TSCmKO mice as previously reported [14] and
now confirmed in a new set of mice (Fig. 1d, e; Additional
file 1: Figure S2D). Besides the changes in blood glucose
and insulin, the concentration of lactate was also in-
creased in TSCmKO mice but not in RAmKO mice
(Fig. 1f). As those plasma profiles suggest changes in the
glucose uptake capacity, we next performed glucose and
insulin tolerance tests. They revealed that TSCmKO mice
were glucose intolerant (Fig. 1g) and slightly more sensi-
tive to insulin (Fig. 1h). RAmKO mice had the reciprocal
phenotype with normal glucose tolerance (Fig. 1g) but
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insulin resistance (Fig. 1h). A similar reciprocal phenotype
was observed for the basal metabolism as energy expend-
iture was increased in 10-week-old RAmKO mice but not
in TSCmKO mice (Table 1). Thus, these results show that
some of the early changes in the whole-body metabolism
are differentially affected in RAmKO and TSCmKO mice.
TSCmKO and RAmKO mice are both resistant to a high-fat
diet
To test how the mice perform under metabolic stress,
we fed both RAmKO and TSCmKO mice a HFD for
12 weeks, starting at the age of 8 or 10 weeks, respect-
ively. Neither TSCmKO nor RAmKO mice gained as
much weight as the control mice (Fig. 2a). RAmKO mice
maintained significantly lower fat and lean mass while
on a HFD (Additional file 1: Figure S2E and S2F) as did
TSCmKO mice [14]. Control mice also developed hep-
atic steatosis whereas TSCmKO and RAmKO were re-
sistant (Fig. 2b). Prolonged HFD feeding causes type 2
diabetes [43]. Consistent with the HFD resistance,
plasma glucose levels were reduced in TSCmKO [14]
and RAmKO mice (Additional file 1: Figure S2G). In
addition, RAmKO mice showed an improved glucose
tolerance compared to TSCmKO and control mice
under the HFD (Fig. 2c). In contrast, TSCmKO showed
an increased insulin sensitivity during the HFD when
compared to RAmKO and control mice (Fig. 2d) [14].
As previously shown [14], TSCmKO mice placed on
HFD ate and drank more, showed increased activity and
energy expenditure, but decreased respiratory exchange
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Fig. 1 Alterations of mTORC1 signaling in the skeletal muscle affects whole-body metabolism. a Body weight is lower in TSCmKO (n = 10) and
RAmKO (n = 17) mice at 10 weeks of age when compared to control (Ctrl) mice (n = 14). b–c Lean mass (b) is lower in TSCmKO (n = 13) and
RAmKO (n = 16) mice while fat mass (c) is only decreased in TSCmKO mice (n = 6) when compared to control (Ctrl) mice at 10 weeks of age
(n = 21). d–e Plasma insulin levels (d) and glucose levels (e) are decreased in 10-week-old TSCmKO mice (n = 12) while they are unchanged in
10-week-old RAmKO mice (n = 6) when compared to control (Ctrl) mice (n = 10). f Plasma lactate levels are increased in 10-week-old TSCmKO
mice (n = 6) while they are unchanged in 10-week-old RAmKO mice (n = 6) when compared to control (Ctrl) mice (n = 12). g–h TSCmKO (n = 6)
but not RAmKO mice (n = 6) show glucose intolerance in a GTT (g) while RAmKO (n = 6) but not TSCmKO mice (n = 6) show insulin resistance in
an ITT (h) at 10 weeks of age when compared to control (Ctrl) mice (n = 10). Data presented are all from male mice of the indicated genotypes.
Data represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 2 TSCmKO and RAmKO mice are both resistant to a high-fat diet. a TSCmKO (n = 7) and RAmKO (n = 5) mice do not gain significant weight
on a HFD when compared to control (Ctrl) mice (n = 12). b TSCmKO and RAmKO mice are resistant to HFD-induced hepatic steatosis, shown by
decreased lipid accumulation in Oil Red O-stained liver (n = 3). Arrows indicate Oil Red O-stained lipids. Scale bar: 100 μm. c Twenty-week-old
RAmKO mice (n = 5) show an increased glucose tolerance on a GTT after a HFD when compared to TSCmKO (n = 6) and control (Ctrl) mice
(n = 12). d Twenty-week-old TSCmKO mice (n = 6) show increased insulin sensitivity on an ITT after a HFD when compared to RAmKO (n = 5)
and control (Ctrl) mice (n = 12). Data presented are all from male mice of the indicated genotypes. Data represent mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001
Table 1 CLAMS analysis of 10-week-old TSCmKO and RAmKO mice
Ctrl TSCmKO P Ctrl RAmKO P
Drink (ml/g/day) 0.31 ± 0.04 0.34 ± 0.06 NS 0.28 ± 0.04 0.30 ± 0.10 NS
Feed (g/g/day) 0.58 ± 0.17 0.58 ± 0.05 NS 0.42 ± 0.06 0.60 ± 0.14 *
CO2 (l/g/day) 0.37 ± 0.02 0.36 ± 0.03 NS 0.34 ± 0.04 0.41 ± 0.03 *
O2 (l/g/day) 0.39 ± 0.02 0.38 ± 0.02 NS 0.37 ± 0.05 0.44 ± 0.04 *
RER 0.94 ± 0.01 0.93 ± 0.03 NS 0.90 ± 0.01 0.91 ± 0.01 NS
Heat (kcal/h/g) 0.020 ± 0.00 0.019 ± 0.00 NS 0.026 ± 0.00 0.032 ± 0.00 *
X-amb (counts/h) 1078.9 ± 230.2 938.66 ± 314.8 NS 935.3 ± 357.3 938.7 ± 314.8 NS
Y-amb (counts/h) 187.9 ± 45.8 186.1 ± 51.6 NS 169.50 ± 93.17 140.19 ± 61.47 NS
Student’s t test. Values represent mean ± SEM over a period of 3 days. Data presented are of male mice. X-amb and Y-amb refer to ambulatory movement measured by
laser counts in X and Y coordinates
NS not significant
*p < 0.05 (n = 6)
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ratio (Table 2). On the other hand, RAmKO mice
showed a decrease in their activity and the respiratory
exchange ratio (Table 2), indicating a preference for fatty
acid metabolism as a source of energy [12]. These results
show that both activation and inhibition of mTORC1 in
the skeletal muscle conferred resistance to a HFD and
they indicate that different mechanisms underlie this
phenotype.
TSCmKO but not RAmKO mice show changes in other
metabolic organs
The activation state of the serine/threonine kinase pro-
tein kinase B (Akt/PKB) is altered in RAmKO and
TSCmKO mice because of the negative feedback loop
from S6K on IRS1 [42]. Thus, in RAmKO mice, lack of
activation of S6K causes increased phosphorylation of
Akt/PKB [5], whereas Akt/PKB phosphorylation is damp-
ened in TSCmKO mice [4]. As Akt/PKB signaling is an im-
portant regulator of carbohydrate metabolism [35], we next
examined Akt/PKB targets involved in glucose absorption
and storage. As previously shown [5, 14, 31], we confirmed
that glycogen phosphorylase levels were decreased in
RAmKO muscle, as well as glycogen synthase phosphoryl-
ation (Fig. 3a) while they were unchanged in TSCmKO
muscle. Moreover, phosphorylation of the Akt/PKB sub-
strate of 160 kDa (AS160/TBC1D4), responsible for glucose
transporter 4 (GLUT4) translocation to the sarcolemma
upon insulin stimulation [6], was decreased in TSCmKO
when measured relative to the amount of TBC1D4. Simi-
larly, phosphorylation of TBC1D1, another Akt/PKB sub-
strate involved in basal glucose absorption into the skeletal
muscle [6], was also reduced in TSCmKO muscle relative
to the total amount of TBC1D1 (Fig. 3a). Interestingly, both
TBC1D4 and TBC1D1 protein levels were increased in
TSCmKO muscle (Fig. 3a). In contrast, phosphorylation of
TBC1D4 was increased in RAmKO muscle and there was a
trend for increased TBC1D1 phosphorylation (Fig. 3a).
Overall, the observed changes correlated well with the in-
creased glycogen levels (Fig. 3b and Additional file 1: Figure
S3A). Thus, modifications of the mTORC1 activity in the
skeletal muscle lead to dysregulated Akt/PKB signaling that
result in changes in glucose transport and storage.
We have previously reported that TSCmKO mice show
browning of white adipose tissue and increased fatty acid
oxidation in the liver [14]. In contrast to the decrease in
lipids in TSCmKO mice (Fig. 3c), lipid content seemed
unchanged in RAmKO liver (Fig. 3c). In agreement with
this, plasma non-esterified fatty acids were decreased in
TSCmKO mice but were the same as in the controls or
RAmKO mice (Fig. 3d). We decided to analyze Akt/PKB
signaling in the liver because insulin is a key regulator of
gluconeogenesis and glycogenolysis in this organ. While
Akt/PKB and mTORC1 activities were unchanged in
RAmKO mice, both were downregulated in the liver of
TSCmKO mice (Fig. 3e). This is likely a consequence of
the decreased plasma insulin levels of the TSCmKO mice
and not lack of responsiveness, as the liver from TSCmKO
mice responded to insulin-like controls (Additional file 1:
Figure S3B). Moreover, the amount of glucose-6 phosphat-
ase was higher in TSCmKO mice than in the controls or
RAmKO mice (Fig. 3e). In correlation with these protein
changes, the glycogen amount was reduced in the livers
from TSCmKO but not from RAmKO mice (Fig. 3f). In
addition, none of the genes that were reported to be chan-
ged in TSCmKO mice involved in fatty acid or glucose
metabolism in the liver; white adipose tissue or brown fat
of TSCmKO mice [14] were changed in RAmKO mice
(Additional file 1. Liver: Figure S3C, S3E, and S3F; white
adipose tissue: Figure S3C; brown fat: Figure S3D). These
results show that under a normal diet, mTORC1 activa-
tion in the skeletal muscle causes changes in other meta-
bolic organs, such as the liver and adipose tissue. In
contrast, the effect of its inhibition is limited to the tar-
geted skeletal muscle.
Table 2 CLAMS analysis of TSCmKO and RAmKO mice on a HFD
Ctrl TSCmKO P Ctrl RAmKO P
Drink (ml/g/day) 0.11 ± 0.04 0.16 ± 0.02 ** 0.15 ± 0.03 0.15 ± 0.06 NS
Feed (g/g/day) 0.21 ± 0.06 0.36 ± 0.12 * 0.27 ± 0.02 0.29 ± 0.13 NS
CO2 (l/g/day) 0.24 ± 0.03 0.32 ± 0.02 *** 0.29 ± 0.04 0.30 ± 0.04 NS
O2 (l/g/day) 0.31 ± 0.04 0.41 ± 0.02 ** 0.36 ± 0.04 0.40 ± 0.06 NS
RER 0.75 ± 0.01 0.77 ± 0.01 ** 0.79 ± 0.01 0.75 ± 0.01 **
Heat (kcal/h/g) 0.021 ± 0.00 0.028 ± 0.00 ** 0.019 ± 0.00 0.020 ± 0.00 NS
X-amb (counts/h) 557.5 ± 122.4 616.9 ± 80.6 NS 601.2 ± 103.8 294.7 ± 71.1 **
Y-amb (counts/h) 55.5 ± 7.8 79.1 ± 25.1 0.05 49.4 ± 10.5 42.3 ± 15.9 NS
Student’s t test. Values represent mean ± SEM over a period of 4 days. Data presented are of male mice. X-amb and Y-amb refer to ambulatory movement measured by
laser counts in X and Y coordinates
NS not significant
*p < 0.05
**p < 0.01
***p < 0.001 (n = 6)
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Strong downregulation of metabolic genes and increased
levels of HDACs in RAmKO skeletal muscle
Uncoupling proteins (UCPs) uncouple the proton gradi-
ent in the inner membrane of the mitochondria thereby
regulating efficiency of ATP production and energy ex-
penditure in cells [1]. In WAT, mTORC1 regulates UCP
expression [27]. Thus, we determined mRNA and pro-
tein levels of UCP in the skeletal muscle. Both mRNA
and protein abundance of UCP2 and of the muscle-
specific UCP3 were significantly increased in RAmKO
mice (Fig. 4a, b). Whereas ATP levels in TSCmKO mice
are reduced, whose muscles also contain a higher
amount of UCP2 [14], the ATP content in the muscle of
RAmKO mice was identical to controls (Additional file
1: Figure S4). Besides the changes in UCPs, expression
of genes involved in fatty acid transport and oxidation,
like Fatp4, Fabp3, or Cpt1b, was decreased in the muscle
of young RAmKO mice compared to control littermates
(Fig. 4c). In addition, expression of glucose transporters
and genes involved in glycolysis was also reduced in
RAmKO skeletal muscle (Fig. 4d), as opposed to the in-
creased expression of genes involved in glucose absorp-
tion and fatty acid oxidation seen in TSCmKO muscle
[14]. To better understand the possible pathways in-
volved in the regulation of those metabolic genes, we
next analyzed the expression of class II histone deacety-
lases 4 and 5 (HDAC4 and HDAC5), which are known
to regulate glycolytic proteins [23, 37]. HDAC4 and
HDAC5 protein levels were increased in RAmKO mice,
while there was only a slight, but significant increase of
HDAC4 in TSCmKO muscle (Fig. 4e). Thus, the strong
increase in HDAC4 and HDAC5 in RAmKO skeletal
muscle could contribute to the decreased expression of
genes involved in fatty acid and glucose metabolism.
Myopathy pre-dominates the metabolic changes in the
two animal models at older age
Previous work has shown that both RAmKO and
TSCmKO mice develop a myopathy [5, 7]. To investi-
gate whether the metabolic changes in peripheral organs
would also converge at older age, we next compared the
overall metabolism between 20-week-old RAmKO and
40-week-old TSCmKO mice, the age at which the myop-
athy is fully developed [5, 7]. Body weights were signifi-
cantly reduced in male and female TSCmKO and male
RAmKO mice (Fig. 5a; Additional file 1: Figure S5A),
which was due to lower lean (Fig. 5b; Additional file 1:
Figure S5B) and fat mass (Fig. 5c; Additional file 1:
Figure S5C). Basal metabolic analysis revealed an in-
crease in energy expenditure in 40-week-old TSCmKO
mice, while in 20-week-old RAmKO mice, the overall
energy expenditure was now as in controls (Table 3).
Analysis of the blood plasma revealed that insulin
(Fig. 5d) and glucose (Fig. 5e) levels were reduced in
both TSCmKO and RAmKO mice, while the increased
plasma lactate levels of young TSCmKO mice (see
Fig. 1f ) were normalized in the old mice (Fig. 5f ). It is
well established that loss of muscle mass also affects glu-
cose metabolism [30, 34]. While glucose tolerance was
normal (Fig. 5g), both TSCmKO and RAmKO mice were
now insulin resistant (Fig. 5h). Insulin resistance in
muscle has been linked to the disruption of lipid dynam-
ics and accumulation of intramyocellular, lipotoxic inter-
mediates [2]. Thus, we analyzed lipid content in the
muscle of the mutant mice and found that lipid droplets
accumulated in RAmKO muscle and the amount of
lipids was increased in TSCmKO muscle (Fig. 5i). These
results suggest that the myopathy in RAmKO and
TSCmKO mice results in very similar overall perturb-
ation of the metabolism.
We previously reported that the myopathy of RAmKO
mice is particularly severe in the diaphragm, which led
us to suggest that respiratory failure might be the cause
of death [5]. Low respiration reduces oxygen saturation
and causes the accumulation of carbon dioxide in the
blood. Blood gas analysis revealed that oxygen and car-
bon dioxide pressure in the blood was the same as in
the controls in 10-week-old RAmKO, but oxygen levels
dropped and carbon dioxide increased in 20-week-old,
myopathic RAmKO mice (Additional file 2: Table S2).
The increase in carbon dioxide also resulted in the low-
ering of the blood pH indicative of respiratory acidosis
(Additional file 2: Table S2). Although we cannot rule out
respiratory complications in old, myopathic TSCmKO
(See figure on previous page.)
Fig. 3 TSCmKO but not RAmKO mice show changes in non-targeted metabolic organs. a Immunoblots of TA muscle from 10-week-old TSCmKO,
RAmKO, and control (Ctrl) mice are shown for the indicated phospho (P)- and total proteins (n = 4). Protein expression is normalized to α-actinin.
Quantification of phosphorylation is shown relative to the total amount of each protein except for P-S6. b Glycogen amount is increased in the
gastrocnemius muscle of 12-week-old RAmKO mice (n = 5) compared to TSCmKO (n = 7) and control (Ctrl) mice (n = 13). c Liver lipid content is
decreased in 12-week-old TSCmKO as shown by Oil Red O staining, while it is unchanged in 10-week-old RAmKO mice (n = 3). Scale bar: 100 μm.
d The concentration of non-sterified fatty acids in the plasma is decreased in 10-week-old TSCmKO mice (n = 4) compared to RAmKO (n = 6) and
control (Ctrl) mice (n = 8). e Immunoblots of the liver from 10-week-old TSCmKO, RAmKO, and control (Ctrl) mice are shown for the indicated
phospho (P)- and total proteins (n = 4). Protein expression is normalized to β-actin. Quantification of the phospho-protein is shown relative to the
amount of each protein. f Glycogen amount is decreased in the liver from 12-week-old TSCmKO mice (n = 4) compared to RAmKO (n = 3) and
control (Ctrl) mice (n = 6). Data presented are all from male mice of the indicated genotypes. Data represent mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001
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mice [7], we observed that 40-week-old TSCmKO mice
also had polycystic kidneys (Additional file 1: Figure S5D),
a frequent cause for acute kidney failure [44]. In agree-
ment with the conclusion that the kidneys were damaged,
the amount of creatinine and lactate dehydrogenase
(LDH) was significantly elevated in the blood of TSCmKO
mice (Table 4). In addition, alanine aminotransferase
(ALTL) and aspartate aminotransferase (ASTL) were also
increased in the plasma of 40-week-old TSCmKO mice
(Table 4), which are commonly used as markers for liver
damage [24]. We hypothesize that this kidney damage in
old TSCmKO mice was the consequence of prolonged
muscle breakdown or rhabdomyolysis [39]. These results
suggest that the disease is mainly restricted to the skeletal
muscle in the RAmKO mice and thus the mice are likely
to die of respiratory failure. In contrast, TSCmKO mice
show defects in several tissues and thus they might suc-
cumb to diseases in multiple organs, including the skeletal
muscle and kidney.
Discussion
The control of energy balance plays a central role in meta-
bolic diseases such as type 2 diabetes and obesity.
mTORC1 has been postulated to play an essential role in
glucose homeostasis by fine-tuning insulin signaling
through Akt/PKB and by controlling metabolic pathways
in different tissues [40, 41]. Likewise, mTORC1 has a cen-
tral role in regulating lipid metabolism and adipogenesis
by activating essential transcription factors like peroxi-
some proliferator-activated receptor gamma (Pparg) and
sterol regulatory element binding protein 1 (Srebp1) [19].
The skeletal muscle is a particularly important player in
the regulation of energy balance in the body, serving
both as a major glucose and energy-storing tissue, as
well as an avid energy consumer during physical ac-
tivity. mTORC1 also affects muscle mass and integrity
by regulating both protein synthesis and degradation,
and it has been suggested to be involved in muscle
wasting during aging [38]. However, how mTORC1
m
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activity in the skeletal muscle affects whole-body me-
tabolism has not yet been clarified in detail.
Consequences of mTORC1 perturbation have been de-
scribed in other metabolic tissues, such as WAT or the
liver, and revealed differential effects of mTORC1 signal-
ing on tissue and whole-body metabolism, depending on
the targeted organs and the mouse models used. For in-
stance, although mTORC1 promotes lipogenesis in the
liver cells through sterol regulatory element binding pro-
tein (SREBP) activation, this effect was abolished in mice
with liver-specific depletion of TSC1 and also resulted in
insulin resistance, due to the simultaneous inhibition of
P
la
sm
a
In
su
lin
(n
g
/m
l)
A
Ctrl-40wk TSCmKO Ctrl-20wk RAmKO
0
4
8
12
B C
D E
G
lu
co
se
%
F
H
I
G
Ctrl RAmKO TSCmKO
Fig. 5 Myopathy pre-dominates the metabolic changes at higher age. a Body weight is decreased in both TSCmKO (n = 8) and RAmKO (n = 4)
mice at 40 and 20 weeks of age, respectively, when compared to control (Ctrl) littermates (n = 9). b–c Both lean mass (b) and fat mass (c) are
decreased in TSCmKO (n = 10) and RAmKO (n = 8) mice at 40 and 20 weeks of age, respectively, when compared to control (Ctrl) littermates
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**p < 0.01, ***p < 0.001
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Akt/PKB in this tissue [22, 26, 46]. Inactivation of
mTORC1 in WAT caused the browning and reduction
of fat, resulted in an increase in energy expenditure, and
Akt/PKB-dependent insulin sensitivity [28].
In our study, we now report on the whole-body conse-
quences of mTORC1 activation and inhibition in the
skeletal muscle (Fig. 6). At a young age, mTORC1 inhib-
ition had a stronger effect on the skeletal muscle, caus-
ing a significant reduction in lean mass and muscle
atrophy [5]. Only few changes were observed at the
metabolic level in RAmKO mice, one being increased
energy expenditure, most likely a consequence of the
higher UCP2 and UCP3 mRNA and protein amount in
the muscle. However, RAmKO mice were insulin resist-
ant, which could be a direct consequence of the early
muscle atrophy and dysfunctional muscle dynamics.
Conversely, at this young age, activation of mTORC1 in
the skeletal muscle caused strong changes of the metab-
olism without yet affecting the structural integrity of the
skeletal muscle. We have previously shown that
mTORC1 activation induces the release of fibroblast
growth factor 21 (FGF21) from the skeletal muscle,
which in turn is responsible for several of the metabolic
changes, such as hypoglycemia, increased fatty acid oxi-
dation, and reduced body weight [14]. Despite the im-
proved metabolic profile of TSCmKO mice, we now
show that they are glucose intolerant. We suggest that
this could be a consequence of dampened Akt/PKB
signaling and the decreased translocation of glucose
transporters to the plasma membrane [6]. Surprisingly,
Akt/PKB signaling was also decreased in the liver of
TSCmKO, likely due to decreased plasma insulin con-
centrations. In addition, the glycogen amount in the liver
was lower in TSCmKO mice, which correlated with an
increase in glucose 6-phosphatase, suggesting increased
liver glycogenolysis as compensation for the low plasma
glucose concentration. In contrast to the TSCmKO
mice, RAmKO mice showed no changes in their liver or
plasma profile, indicating that the consequences of early
mTORC1 inhibition are limited to the skeletal muscle.
Interestingly, even if RAmKO and TSCmKO mice ini-
tially show an opposite metabolic phenotype, both mu-
tant mice are resistant to HFD. Both mutant mice did
not gain weight nor did they develop hepatic steatosis
on a 12-week-long HFD. However, while TSCmKO mice
showed increased insulin sensitivity and seemed to
Table 4 cobas analysis of 40-week-old TSCmKO and 20-week old RAmKO plasma
Group ALTL (U/l) ASTL (U/l) Uric acid (μmol/l) Creatinine
(μmol/l)
LDH
(mmol/l)
TRIGL
(mmol/l)
HDL-Chol
(mmol/l)
LDL-Chol
(mmol/l)
Chol
(mmol/l)
Ctrl 40.5 ± 4.3 65.7 ± 10.5 220.8 ± 54.0 10.7 ± 1.7 256.5 ± 76.1 1.1 ± 0.2 2.5 ± 0.5 0.3 ± 0.0 2.7 ± 0.6
TSCmKO 85.4 ± 13.6 308.9 ± 53.3 244.1 ± 60.6 16.6 ± 0.6 567.2 ± 74.2 1.1 ± 0.2 2.26 ± 0.3 0.4 ± 0.0 2.6 ± 0.3
P ** *** NS *** *** NS NS ** NS
Ctrl 31.5 ± 4.7 60.3 ± 14.3 115.3 ± 24.6 16.1 ± 1.7 278.0 ± 99.3 0.7 ± 0.5 2.0 ± 0.3 0.2 ± 0.0 2.3 ± 0.3
RAmKO 38.4 ± 8.7 95.2 ± 12.8 118.8 ± 28.5 15.5 ± 1.9 412.4 ± 58.7 0.5 ± 0.4 1.9 ± 0.2 0.2 ± 0.0 2.3 ± 0.3
P NS * NS NS NS NS NS NS NS
Values represent mean ± SEM of male mice. Student’s t test
NS not significant
*p < 0.05
**p < 0.01
***p < 0.001 (n = 5)
Table 3 CLAMS analysis of 40-week-old TSCmKO and 20-week-old RAmKO mice
Ctrl TSCmKO P Ctrl RAmKO P
Drink (ml/g/day) 0.18 ± 0.05 0.22 ± 0.07 NS 0.23 ± 0.11 0.14 ± 0.03 NS
Feed (g/g/day) 0.31 ± 0.09 0.40 ± 0.12 NS 0.37 ± 0.19 0.44 ± 0.13 NS
CO2 (l/g/day) 0.28 ± 0.03 0.32 ± 0.04 * 0.25 ± 0.05 0.26 ± 0.02 NS
O2 (l/g/day) 0.32 ± 0.03 0.37 ± 0.04 * 0.28 ± 0.05 0.30 ± 0.03 NS
RER 0.85 ± 0.05 0.88 ± 0.05 NS 0.88 ± 0.04 0.87 ± 0.01 NS
Heat (kcal/h/g) 0.022 ± 0.00 0.028 ± 0.00 * 0.026 ± 0.00 0.028 ± 0.00 NS
X-amb (counts/h) 884.1 ± 316.4 578.1 ± 113.1 0.05 820.7 ± 247.7 856.6 ± 434.9 NS
Y-amb (counts/h) 117.1 ± 43.1 75.8 ± 19.5 0.09 100.2 ± 56.4 130.0 ± 48.8 NS
Student’s t test. Values represent mean ± SEM over a period of 3 days. Data presented are of male mice. X-amb and Y-amb refer to ambulatory movement measured by
laser counts in X and Y coordinates
NS not significant
*p < 0.05 (n = 6)
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accelerate their metabolism by eating more and being
more active, RAmKO mice showed improved glucose
tolerance and slowed their metabolism by decreasing the
activity and their respiratory exchange ratio. All these
metabolic changes, compared to those previously re-
ported, point to the specific consequences of mTORC1
deregulation depending on the metabolic organs in
which the perturbation occurs.
Consistent with the inhibition of mTORC1 activity,
RAmKO mice display a downregulation of glycolytic
proteins and genes involved in fatty acid oxidation in the
skeletal muscle. This correlated with the increase in class
II HDACs, which have been described to regulate the
transcription of glycolytic proteins [8]. The inefficient
nutrient utilization and the increased energy demand
might lead to beneficial systemic effects and to a resist-
ance to diet-induced obesity in the RAmKO mice. This
phenotype is paralleled by a reduction of the oxidative
capacity of the muscles and by a reduction of the num-
ber of mitochondria [31]. Similar to RAmKO mice,
treatment with rapamycin leads to a reduced glucose up-
take [3], which highlights the critical role of muscle
mTORC1 signaling.
Changes in muscle integrity can affect whole-body me-
tabolism, as seen in patients with muscular dystrophies
who often develop glucose intolerance and insulin resist-
ance [9, 34]. Both TSCmKO and RAmKO mice develop
a myopathy and show a reduced body weight, which
suggested that they are not able to gain lean and fat
mass with age as control mice do. Interestingly, myo-
pathic RAmKO and TSCmKO mice develop insulin re-
sistance and show lower plasma glucose and plasma
insulin concentrations. It has been proposed that whole-
body insulin resistance is a consequence of lipotoxicity
caused by aberrant lipid metabolism in the muscle and
increased intramyocellular accumulation of ceramides
and diacylglycerol [2]. Accordingly, TSCmKO and
RAmKO mice could suffer from lipotoxicity as they
showed increased accumulation of lipids in the skeletal
muscle. This accumulation of toxic lipid intermediates
could be a result of endoplasmic reticulum stress in
TSCmKO mice [14, 32] and activation of inflammatory
pathways in RAmKO mice [5, 25]. Nonetheless, the de-
velopment of insulin resistance in both mouse models
after the onset of the myopathy is well in line with the
metabolic complications in muscular dystrophies. It will
be interesting to see whether deregulation of mTORC1
signaling could also be at the onset of those metabolic
complications in muscular dystrophies.
Our results indicate that mTORC1 is a central control-
ler of metabolic properties of muscle tissue by affecting
fatty acid and glucose metabolism, glycogen storage, and
oxidative capacity. We also show that the skeletal muscle
mTORC1 plays an essential role in whole-body homeosta-
sis and energy expenditure. Our data imply that the bene-
ficial effects of rapamycin on systemic metabolism and
longevity could in part be based on inhibition of mTORC1
in the skeletal muscle. Therefore, further investigation
should be conducted to determine whether mTORC1 de-
regulation in muscular dystrophies might be the cause of
the overall changes in the whole-body metabolism.
Conclusions
In this study, we have confirmed that alterations to
mTORC1 signaling pathway in the skeletal muscle directly
affect whole-body metabolism, which highlights the import-
ance of this tissue in maintaining energy stability. Moreover,
we show that a proper balance in mTORC1 signaling is es-
sential for muscle integrity and metabolic homeostasis, as
both long-term activation and inhibition originate a myop-
athy that mimics the main metabolic complications of dys-
trophic patients. Thus, muscle mTORC1 could serve as a
potential target to treat those metabolic complications.
Additional files
Additional file 1: Supplementary Figures S1 to S5. Figure S1.
Unchanged expression of Actb. (A) Actb (encoding β-actin) expression in
the muscle, liver, WAT, and BAT of control (n=5) and RAmKO mice (n=5).
Fig. 6 Summary of metabolic changes induced by altered mTORC1
signaling in the skeletal muscle of mice during aging
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(B) List of antibodies used. Figure S2. Metabolism of female TSCmKO and
RAmKO mice. (A) Body weight, (B) lean mass, (C) fat massand (D) plasma
glucose levels of 10-week-old female TSCmKO (n=9), RAmKO (n=8) and
control (Ctrl) mice (n=11). (E)–(G) Fat mass (E), lean mass (F) and plasma
glucose levels (G) of male RAmKO (n=4) and control (Ctrl) mice (n=6) on
a HFD. Figure S3. RAmKO mice do not show changes in other organs. (A)
Glycogen amount in gastrocnemius muscle of 10-week-old TSCmKO
mice (n=3). (B) Western blot analysis of liver from 10-week-old TSCmKO
and control (Ctrl) mice (n=4). Mice were intraperitoneally injected with
insulin (+; TSC-insulin) or not (−). Protein expression is normalized to
eEF2. (C)–(D) 12-week-old RAmKO mice do not show changes in Ucp2
expression in the liver and WAT (C) or Ucp1 and Ucp2 in BAT (D)
compared to control mice (n=5). (E)–(F) Liver expression of genes
involved in lipid (E) and glucose (F) metabolism of RAmKO mice (n=5).
Figure S4. ATP levels in 12-week-old RAmKO soleus muscle (n = 5). Figure
S5. Body composition in myopathic female TSCmKO and RAmKO mice.
(A) Body weight, (B) lean and (C) fat mass of 40-week-old TSCmKO
(n=10), 20-week-old RAmKO (n=4) and respective control (Ctrl) littermates
(n=11). (D) The kidneys of 40-week-old TSCmKO mice appear polycystic.
Cysts are indicated by arrows.
Additional file 2: Supplementary Tables S1 and S2. Table S1. List of
primers used. Table S2. RAmKO blood analysis.
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